Gastroparesis Drugs Market by Drug Class (Prokinetic Agents, Antiemetic Agents, and Botulinum Toxin Injections), Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, and Post-Surgical Gastroparesis), and End User (Hospitals, Pharmacies, Clinics, and E-commerce) - Global Opportunity Analysis and Industry Forecast, 2017-2023

  • ALL2231664
  • 231 Pages
  • November 2017
  • Pharmaceuticals

The global gastroparesis market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023. Gastroparesis is a medical condition of the stomach, which affects the normal spontaneous movement of the muscles of the stomach. It restricts the normal digestion, causes vomiting, and problems related with blood sugar levels & nutrition. Various medications or drugs are prescribed to treat gastroparesis, such as reglan, erythromycin, antiemetics, and others.

Rise in number of surgeries, which leads to postsurgical gastroparesis conditions is the major factor that contributes to the growth of the gastroparesis drugs market. Moreover, rise in diabetic population, increase in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting fuel the market growth. However, side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis hamper the growth of the market. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.

The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.


  • The study provides an in-depth analysis of the global gastroparesis drugs market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
  • Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.


By Drug Class

  • Prokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin Injections

By Disease Type

  • Diabetic Gastroparesis
  • Idiopathic Gastroparesis
  • Post-surgical Gastroparesis
  • Others

By End User

  • Hospitals
  • Pharmacies
  • Clinics
  • E-commerce

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA


  • Allergan, Plc.
  • Abbott Laboratories (Abbott Arzneimittel GmbH)
  • AstraZeneca Plc.
  • Cadila Pharmaceuticals Ltd.
  • ETX Pharma, Inc
  • Evoke Pharma
  • GlaxoSmithKline Plc.
  • Neurogastrx, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Theravance Biopharma

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

  • Altos Therapeutics LLC
  • Mylan N.V.
  • Hexal AG
  • CEVA Group PLC
  • Takeda Pharmaceutical Company Ltd
Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+91 20 66346066
--- or ---



Global General Medicine Education Publishing Market (Type, Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast (2013-2020)

General medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs. It is also called as Internal Medicine. General medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students.

April 2018| $5370 | Pre Book Price:$4699

Cancer Vaccine Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system�s ability to fight against infections and diseases. It is used either as stand-alone therapies ...

April 2018| $4995 | Pre Book Price:$4371

World Active Pharmaceutical Ingredient (API) Market - Opportunities and Forecasts, 2014 - 2020

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) ...

April 2018| $5370 | Pre Book Price:$4699

Anterior Uveitis Asia-Pacific Market Research Report, 2014 - 2020

Anterior uveitis is an eye inflammation that involves middle layer of the eye specifically, iris (colored part of the eye) and ciliary body (adjacent tissue). Untreated anterior uveitis results in ...

April 2018| $2850 | Pre Book Price:$2494

Nanomedicine Asia-Pacific Market Research Report, 2014 - 2020

Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and ...

April 2018| $2850 | Pre Book Price:$2494

Autoimmune Disorders Treatment Asia-Pacific Market Research Report, 2014 - 2020

Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in ...

April 2018| $2850 | Pre Book Price:$2494

2018 © Copyright Big Market Research

View Pricing >>